We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 24,007 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/2/2018 11:40 | Eddie couldn't agree more. the constant ramping on brazenly outrageous assumptions that 2+2 = 4 equals = loads of deals = £'s by end of year is quite naive. | ih_575893 | |
24/2/2018 11:31 | Parob, I said in an earlier post that the only thing that separates us from a three figure share price is two pieces of news and both of those near term, especially Nuvec that could be any day. Personally, from what I know I am fully confident that both will be a complete success and that sildenafil will be followed by other blockbusters. I could be wrong but I see nothing to suggest that, it`s all just a question of time. | hughwilson | |
24/2/2018 09:54 | As we know N4P have two potential ‘game changers’ at the moment (there could be more in the future): Sildenafil and Nuvec. We just need one of these to be a success and we’re looking at a share price in the pounds IMO. If both are a success I wouldn’t want to hazard a guess at where the share price could end up. At this stage, everything is going to plan and I know I keep harping on about it but the AZ collaboration was even ahead of the company’s anticipated schedule. Hugh, this article you posted yesterday was a great find and definitely worth a read: | parob | |
23/2/2018 19:00 | Eddie, not blatant rampimg but the product of research and logic. I would suggest you try it sometime. | hughwilson | |
23/2/2018 18:56 | Not a personal vendetta Hugh, I just think your blatant ramping is way ott. | eddie_yates | |
23/2/2018 18:22 | Eddie, you are sounding like for you this is a personal vendetta. I would suggest that rather than spending all your time trying to pick holes in what I say, you should spend it contributing something of substance or value to investors rather than forever seeking to stick the dagger in. However I will answer your attack. Three months is the timeframe during which N4`s nanoparticles will be lent out to Japanese pharma`s under a marketing contract. If they like what they see then they will either sign a deal or a collaboration leading to a deal. Given that N4`s particles are far superior to those presently used, why would the Japanese pharma`s wish to revert to the inferior one when N4`s offer a solution to their delivery problems. The timeframe of three months is the evaluation period and is also the timeframe of British Embassy support. Three months is therefore the timeframe in which to expect news of deals or collaborations. | hughwilson | |
23/2/2018 18:03 | Hugh you are a complete tool imho How on earth can the 2 assumptions you’ve made below equate to a very specific timeframe, ie 3 months!!! hughwilson23 Feb '18 - 16:41 - 2489 of 2491 Assuming there is a take up of N4's nanoparticles, from this meeting onwards there will be any number of Japanese pharmas working with N4's particles in their labs. Assuming they are all impressed with the results then it is just a question of time ie three months, before the deals start rolling in. | eddie_yates | |
23/2/2018 17:11 | "If you're on the investor side and you're wondering what sort of a company would be worthwhile investing in the long term, a strong Japan story is a positive. Japan has the most well-defined regulatory system and the easiest to understand regulatory pathway. If you're a biotech and you're not already looking toward Japan, you're missing a golden opportunity" | hughwilson | |
23/2/2018 16:54 | There are no codes and market makers and their automated systems simply react to supply and demand . . . It's basic economics . . . | cufes2 | |
23/2/2018 16:41 | Assuming there is a take up of N4's nanoparticles, from this meeting onwards there will be any number of Japanese pharmas working with N4's particles in their labs. Assuming they are all impressed with the results then it is just a question of time ie three months, before the deals start rolling in. | hughwilson | |
23/2/2018 16:11 | You wouldn't want to be out of this over the weekend | deltrotter | |
23/2/2018 15:46 | TBF the share price has pretty much followed the path of the trades today - chilling on a Friday ! | urigem | |
23/2/2018 15:40 | CuFeS2 This is Aim you don't think city use codes ! you try buying now , they drop the share price on many small trades to fill their orders simple Bet no one could buy with NT or K & F Told Ya ! | sep800 | |
23/2/2018 15:24 | Mms doing their best but N4P bouncing back:))) | ch1rp | |
23/2/2018 14:53 | There are no "codes" . . . It's simply brokers balancing/correcting their books . . . | cufes2 | |
23/2/2018 14:19 | And the MM`s prepare for trading by dropping the spread. | hughwilson | |
23/2/2018 14:14 | Good week again, looking forward to the coming months | urigem | |
23/2/2018 14:06 | Expecting a late afternoon push as usual?! Wouldn't be surprised if we get a round up of what happened in Japan RNS Monday. | deeppockets | |
23/2/2018 14:05 | I thought the 1 was for a £1 bid. 2 for a £2 bid and so on | deltrotter | |
23/2/2018 14:03 | code 1 = rns due | sep800 | |
23/2/2018 14:01 | Isn't the 1 trade a signal that a bid is coming? | deltrotter | |
23/2/2018 13:59 | Something tells me maybe not so too good news for now those 4858 trades in a row is city code trades followed by rns code 1 | sep800 | |
23/2/2018 13:57 | So somebody/people sell the exact same quantity of shares at 1 minute intervals do they? PS. there is that 1 share sale. RNS alert? | hughwilson | |
23/2/2018 13:48 | The MMS aren't suppressing anything . . . They simply make a market and react to supply and demand because they generally keep a flat book . . . They make their money on the spread . . . | cufes2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions